The Korean Journal of Medicine

  • 제84권5호
  • /
  • Pages.690-697
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

다발골수종의 Cyclophosphamide 및 Prednisone 복합화학요법의 효과

Effect of Cyclophosphamide and Prednisone as a First-line Treatment for Non-transplant Candidates with Multiple Myeloma

  • 유미라 (조선대학교 의과대학 내과학교실 종양혈액내과) ;
  • 임현종 (조선대학교 의과대학 내과학교실 종양혈액내과) ;
  • 이희정 (조선대학교 의과대학 내과학교실 종양혈액내과) ;
  • 김형호 (조선대학교 의과대학 내과학교실 종양혈액내과) ;
  • 문우람 (조선대학교 의과대학 내과학교실 종양혈액내과) ;
  • 정춘해 (조선대학교 의과대학 내과학교실 종양혈액내과) ;
  • 박치영 (조선대학교 의과대학 내과학교실 종양혈액내과) ;
  • 박상곤 (조선대학교 의과대학 내과학교실 종양혈액내과)
  • You, Mi-Ra (Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University) ;
  • Lim, Hyun-Jong (Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University) ;
  • Lee, Hee-Jeong (Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University) ;
  • Kim, Hyung-Ho (Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University) ;
  • Moon, Woo-Ram (Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University) ;
  • Chung, Choon-Hae (Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University) ;
  • Park, Chi-Young (Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University) ;
  • Park, Sang-Gon (Department of Internal Medicine, Hemato-oncology College of Medicine, Chosun University)
  • 투고 : 2012.08.20
  • 심사 : 2012.11.06
  • 발행 : 2013.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

본 연구는 3회 이하로 투여된 환자가 13명으로 총 29명 중 상대적으로 많은 환자에서 빨리 중단되었고 후향적 분석으로 의무기록에 근거하여 기록하여 약제의 정확한 치료 효과 및 부작용을 판별하는 점은 쉽지 않았다는 한계점은 있다. 그러나 다발골수종은 고령에서 발생하고 진단 당시 합병증이 있는 경우가 많으며 연령이나 활동도 또는 합병증, 여러 경제적 상황들로 조혈모세포 이식을 시행하기가 불가능한 경우가 많다. 현재 많은 표적 치료제가 임상에 적용되고는 있으나 많은 제약점으로 여전이 과거의 알킬화 제제를 이용한 항암화학요법이 현재도 유용하게 사용되고 있는 현재 임상 상황에서 melphalan과 prednisone 복합요법보다 부작용에 이 적고 정주를 통해 체내 일정 농도의 유지가 가능하며 투여 요법이 간편한, 그리고 보다 중앙 생존 기간의 연장을 보일 수 있는 cyclophosphamide, prednisone 복합요법을 전신상태가 좋지 못한 환자에서 다발성 골수종의 초기 치료로서 사용하는 것도 좋은 치료 전략으로 보인다.

Background/Aims: For many years, conventional treatment for multiple myeloma (MM) not ineligible for high-dose therapy has been the combination of oral melphalan and prednisone (MP). However, melphalan-based regimens are associated with numerous complications. Another alkylating agent, cyclophosphamide, has similar effects on MM and is associated with fewer reports of complications. Therefore, cyclophosphamide-based regimens have usually been used as salvage therapy in patients with refractory or relapsed MM, despite the development of newer drugs. The purpose of this report was to evaluate the efficacy and tolerability of cyclophosphamide and prednisone as a first-line therapy for MM. Methods: For the period January 2002 to June 2012, we retrospectively analyzed 29 patients newly diagnosed with MM who underwent a treatment regimen consisting of intravenous cyclophosphamide (1,000 mg/kg) for 1 day and prednisone (100 mg) for 4 days. Results: The rate of response to this regimen was 31.1 percent. The median progression-free survival (PFS) was 5.5 months and the median overall survival (OS) was 47.3 months. The regimen was well tolerated. Adverse effects of grades above III were as follows: anemia in seven patients (24.1%), neutropenia in five patients (17.2%), and thrombocytopenia in two patients (6.8%). These adverse effects were easily adjusted. No one developed a secondary malignancy or hemorrhagic cystitis. Conclusions: Although PFS was less than for the MP regimen, median OS was better than for the MP regimen. Furthermore, the cyclophosphamide-prednisone regimen was well tolerated, and the adverse effects that did occur were easily adjusted. The cyclophosphamide-prednisone combination regimen may represent an effective and well tolerated first-line therapy for non-transplant candidates with MM.

키워드

참고문헌

  1. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154:32-75. https://doi.org/10.1111/j.1365-2141.2011.08573.x
  2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-1060. https://doi.org/10.1056/NEJMra1011442
  3. Demirer T, Buckner CD, Gooley T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996;17:937-941.
  4. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743-748. https://doi.org/10.1056/NEJM197910043011402
  5. Alexanian R, Haut A, Khan AU, at al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-1685. https://doi.org/10.1001/jama.1969.03160090040009
  6. Rivers SL, Patno ME. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. JAMA 1969;207: 1328-1334. https://doi.org/10.1001/jama.1969.03150200094011
  7. Salokannel SJ, Palva IP, Timonen T, Kaipainen WJ. Cyclophosphamide in the treatment of multiple myeloma. Blut 1971;23:129-132. https://doi.org/10.1007/BF01632279
  8. Cornwell III GG, Pajak TF, Kochwa S. Comparison of melphalan and cyclophosphamide therapy. Br Med J 1971; 1:640-641. https://doi.org/10.1136/bmj.1.5750.640
  9. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420. https://doi.org/10.1200/JCO.2005.04.242
  10. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473. https://doi.org/10.1038/sj.leu.2404284
  11. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9. https://doi.org/10.1038/leu.2008.291
  12. Lee SI, Ko YW, Hahn JS, Kim KS, Chai ES. A clinical study on multiple myeloma. Korean J Med 1976;19:208-217.
  13. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010;28:3160-3166. https://doi.org/10.1200/JCO.2009.26.1610
  14. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917. https://doi.org/10.1056/NEJMoa0801479
  15. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA Trial. J Clin Oncol 2010;28:2259-2266. https://doi.org/10.1200/JCO.2009.26.0638
  16. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010; 116:5838-5841. https://doi.org/10.1182/blood-2010-08-303487
  17. Bergsagel DE, Cowan DH, Hasselback R. Plasma cell myeloma: response of melphalan-resistant patients to highdose intermittent cyclophosphamide. Can Med Assoc J 1972; 107:851-855.
  18. Brandes LJ, Israels LG. Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol 1987;39:362-368.
  19. De Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide- prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 2001;59:50-56. https://doi.org/10.1016/S0300-2977(01)00140-1
  20. Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:4777-4783. https://doi.org/10.1200/JCO.2007.14.2372
  21. Palumbo A, Boccadoro M, Bruno B, Triolo S, Pileri A. Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma. Haematologica 1994;79:513-518.
  22. Lenhard RE Jr, Oken MM, Barnes JM, Humphrey RL, Glick JH, Silverstein MN. High-dose cyclophosphamide: an effective treatment for advanced refractory multiple myeloma. Cancer 1984;53:1456-1460. https://doi.org/10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C
  23. Sharabi A, Laronne-Bar-On A, Meshorer A, Haran-Ghera N. Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. Cancer Prev Res (Phila) 2010; 3:1265-1276. https://doi.org/10.1158/1940-6207.CAPR-10-0138
  24. Sharabi A, Ghera NH. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. Adv Cancer Res 2010;107:1-37. https://doi.org/10.1016/S0065-230X(10)07001-6
  25. Zhou F, Guo L, Shi H, Lin C, Hou J. Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. Clin Lymphoma Myeloma Leuk 2010;10:51-55. https://doi.org/10.3816/CLML.2010.n.005
  26. Mellqvist UH, Lenhoff S, Johnsen HE, et al. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer 2008;112: 129-135. https://doi.org/10.1002/cncr.23145
  27. Song MK, Chung JS, Shin HJ, et al. Cyclophosphamidecontaining regimen (TCD) is superior to melphalancontaining regimen (MPT) in elderly multiple myeloma patients with renal impairment. Ann Hematol 2012;91: 889-896. https://doi.org/10.1007/s00277-011-1401-2
  28. Ogawa M, Bergsagel DE, McCulloch EA. Differential effects of melphalan on mouse myeloma (adj. PC-5) and hemopoietic stem cells. Cancer Res 1971;31:2116-2119.
  29. Gregersen H, Ibsen JS, Nielsen M. Renal insufficiency in myelomatosis: prognostic factors and survival. Ugeskr Laeger 1997;26:3387-3392.